
    
      This is a randomized open label multicenter comparative phase II trial. The objective of the
      study is to investigate whether trabectedin demonstrates sufficient antitumor activity
      against recurrent grade II or III to justify further investigation in phase III or as
      adjuvant therapy for newly diagnosed disease after resection and radiotherapy.
    
  